EGFR and non-small cell lung carcinoma: Although some limitations including small patients number exist in this study, preliminary demonstration of both favorable PK profiles and the efficacy of the combined treatment was encouraging, potentially in NSCLC patients with EGFR-activating mutations, where prior EGFR-TKI treatment failed regardless of EGFR T790M status.